Search PubMed⌕ Search

PubMed · 629313

Surface-active material in human amniotic fluid.

Abstract

Surface-active fractions similar to the biochemical constituents of the pulmonary surfactant system can be isolated from human amniotic fluid and lung tissue from week 10 of gestation through term. Amniotic fluid yielded 10 mg. per 100 ml. surface-active material at 10 to 28 weeks' gestation and 330 mg. per 100 ml. at term. Fetal lung at 10 weeks of gestation gave 1,233 mg. per 100 ml. and 1,670 mg. per 100 ml. at 4 days after birth. The constituent PC of these surface-active fractions from amniotic fluid and lung contained in excess of 60 per cent palmitoyl residues. PC associated with the surface-active fraction accounted for no more than 15 per cent of the total amniotic fluid concentration of this compound. Minimum surface tensions obtained with these preparations from amniotic fluid ranged from 2.5 dynes per centimeter at 33 weeks to 8.3 dynes per centimeter at 40 weeks. At 14 to 28 weeks, the surface-active fraction from lung gave a minimum surface tension of 18.1 dynes per centimeter and 7.0 dynes per centimeter by 4 days after birth. These findings are consistent with the observation that an increase in the activity or concentration of the fetal lung surfactant system takes place in the last 4 weeks of gestation. Some constituents of this system, or their derivatives which have possibly been altered as a result of biochemical changes, are found in amniotic fluid. We infer that the majority of PC in amniotic fluid is not directly associated with the biochemical constituents of the fetal lung surfactant system.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M F Frosolono, J F Roux. 1978-03-01. Surface-active material in human amniotic fluid.. https://doi.org/10.1016/0002-9378(78)90077-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Perinatal outcomes of pregnancies with borderline amniotic fluid index.

OBJECTIVE: Our aim was to determine whether a borderline amniotic fluid index observed during antepartum testing confers a significant risk of adverse perinatal outcome. METHODS: Between April 2001 and May 2005, uncomplicated gestations with a singleton non-anomalous fetus, who underwent weekly monitoring of amniotic fluid index (AFI) until delivery during the last trimester and who gave birth at our hospital, were identified for our study. Normal amniotic fluid volume and borderline amniotic fluid were defined as AFI of >10 and <24 cm and >5 and <10 cm, respectively. The groups were compared on maternal data, mode of delivery and perinatal outcomes such as fetal distress, intrauterine growth restriction and meconium fluid. RESULTS: A total of 90 cases were identified as borderline amniotic fluid and 277 cases as normal AFI. We observed significant increased incidences of admission to neonatal intensive care unit, intrauterine growth restriction, meconium-stained amniotic fluid, intrapartum fetal distress in the group with borderline amniotic index (P < 0.05). CONCLUSIONS: A borderline amniotic fluid index observed in antepartum testing during the last trimester carries an increased risk of adverse perinatal outcomes. These patients should be followed up carefully during the antepartum and intrapartum period.

Amniotic Fluid↗

Isolation of amniotic stem cell lines with potential for therapy.

Stem cells capable of differentiating to multiple lineages may be valuable for therapy. We report the isolation of human and rodent amniotic fluid-derived stem (AFS) cells that express embryonic and adult stem cell markers. Undifferentiated AFS cells expand extensively without feeders, double in 36 h and are not tumorigenic. Lines maintained for over 250 population doublings retained long telomeres and a normal karyotype. AFS cells are broadly multipotent. Clonal human lines verified by retroviral marking were induced to differentiate into cell types representing each embryonic germ layer, including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. Examples of differentiated cells derived from human AFS cells and displaying specialized functions include neuronal lineage cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage cells producing urea, and osteogenic lineage cells forming tissue-engineered bone.

Amniotic Fluid↗